Compare MATV & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MATV | TECX |
|---|---|---|
| Founded | 1995 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 665.6M | 618.9M |
| IPO Year | 1996 | 2018 |
| Metric | MATV | TECX |
|---|---|---|
| Price | $11.59 | $19.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $71.00 |
| AVG Volume (30 Days) | ★ 351.0K | 227.4K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.32% | N/A |
| EPS Growth | N/A | ★ 40.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.75 | N/A |
| Revenue Next Year | $3.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.07 | $15.60 |
| 52 Week High | $15.48 | $39.53 |
| Indicator | MATV | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 49.39 | 29.20 |
| Support Level | $11.14 | $17.27 |
| Resistance Level | $12.65 | $30.80 |
| Average True Range (ATR) | 0.42 | 1.15 |
| MACD | 0.03 | 0.13 |
| Stochastic Oscillator | 48.56 | 4.66 |
Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments, namely Filtration & advanced Materials, focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging, and healthcare solutions.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.